Glutamate and Low Dose Naltrexone (LDN) and MS

"Glutamate excess and its reduction by low dose naltrexone (LDN) are the main facets of the hypothesis proposed by the Cornell pathologist Yash Agrawal in explaining the benefits of LDN described in MS (anecdotally and in clinical trials). In his research, Dr. John Hong a senior scientists at the National Institutes of Health, has shown how glutamate contributes to the disease process in Parkinson’s Disease. In his preliminary studies of low dose opiate antagonists such as naltrexone, Dr. Hong has also shown how these compounds reduce glutamate accumulations and stop disease progression in neurological disorders."

http://autoimmunedisease.suite101.com/article.cfm/glutamate_excess_in_multiple_sclerosis_variants